CompletedNCT00845026
LY2140023 or standard antipsychotic treatment for schizophrenia
About this title
Read the official source — NCT00845026Researchers compared LY2140023, aripiprazole, olanzapine and risperidone, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared LY2140023, aripiprazole, olanzapine and risperidone, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Escondido and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 261
- Sponsor
- Denovo Biopharma LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Germany, Mexico, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00845026
- Official title
Show the full official title
A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido, United States · Garden Grove, United States · Washington D.C., United States
21 more locations
- Chicago, United States
- Hoffman Estates, United States
- Indianapolis, United States
- Lake Charles, United States
- Willingboro, United States
- Amityville, United States
- Oklahoma City, United States
- DeSoto, United States
- Jena, Germany
- Mannheim, Germany
- Wiesbaden, Germany
- Guadalajara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- Khot'kovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared LY2140023, aripiprazole, olanzapine and risperidone, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Who is behind this study?
The study sponsor is Denovo Biopharma LLC.
Did this study involve medication?
Yes. The study involved medication, including LY2140023, aripiprazole, olanzapine and risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia